Is the Fountain of Youth Found in Nanoparticles?
—NanoSphere Announces Anti-Aging Product Using Nano-Sized Particles of Hyaluronic Acid—
NanoSphere Health Sciences, Inc. (CSE:NSHS) (OTC:NSHSF) announced today it has developed an anti-aging product combining
Hyaluronic Acid (HA) with the Company’s patented Nanosphere Delivery System™.
NanoSphere is best known for developing cannabis and CBD products that are delivered via the Company’s patented delivery system.
While that enterprise continues to grow, this is NanoSphere’s first product for the cosmeceutical industry.
Hyaluronic Acid (HA) is a large linear polymer that occurs naturally in the human body and decreases with age. HA is commonly
used to remoisturize dry skin, eliminate wrinkles and treat skin aging as a cosmeceutical. HA is also injected as a dermal filler
by aesthetic surgeons and can be applied to wounds to accelerate healing.
The new product now being tested by NanoSphere is intended to greatly improve the results of Hyaluronic Acid for treating skin
anti-aging without the need for injection.
NanoSphere is also testing the prototype’s effectiveness for treating joint stiffness and arthritic pain. Currently high
molecular weight HA is injected into joints by orthopedic surgeons to reduce pain and improve mobility associated with degenerative
joint disorders. By contrast, topically applied NanoSphere HA is optimized for penetration into the skin, joints and wounds,
delivering greater activity and sustained effects via NanoSphere’s patented nanoparticle delivery system.
“The main issue with Hyaluronic Acid as an anti-aging compound is that the polymer molecules are too large to penetrate through
skin in typical preparations, so It could only be highly effective in therapy when administered through injection or broken into
shorter fragments that may cause inflammation,” explains NanoSphere Chief Science Officer Dr. Richard Kaufman. “Our process
encapsulates pharmaceutical grade HA of higher molecular weights in flexible, deformable patented NanoSphere lipid nanoparticles.
The result is a viscoelastic NanoGel containing flexible nanoparticles of Hyaluronic Acid capable of penetrating the human skin,
aiding delivery to target sites where it is most effective.”
Kaufman says the result is not exactly the same as HA dermal fillers and joint treatments delivered by hypodermic needles, which
may show dramatic results almost immediately. However, the NanoSphere HA solution over a period of weeks can show some remarkable
benefits, says NanoSphere CEO Robert Sutton.
“This research represents a potential breakthrough that will make anti-aging, joint mobility, and wound healing treatments more
affordable and available to the general population,” Sutton said. “We are still studying its long-term effectiveness, but initial
study results are very promising.”
Kaufman says the NanoSphere product is different from current cosmetic HA treatments. NanoSphere HA is able to deliver
Hyaluronic Acid into the epidermis and the joints with high molecular weights greater than 800,000 Daltons, similar to what the
human body forms naturally. As well, the NanoSphere lipid nanoparticles are ‘elastic’ and were shown to better penetrate the skin
than rigid nanoparticles.
Sutton says NanoSphere HA is currently going through internal testing and clinical trials and will be offered for sale only when
that process is complete.
NanoSphere’s Commitment to Licensing IP
NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous
evaluation process. For more information about NanoSphere’s licensing program, please visit:
https://www.nanospherehealth.com/licensing/
About NanoSphere
NanoSphere Health Sciences, Inc. is a biotechnology firm specializing in the creation of the patented NanoSphere Delivery
System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter
medications for the cannabis, pharmaceutical and animal health industries, and beyond. Nanosphere’s ‘Evolve Formulas’ line of
products offer the world's first and only scientifically proven nanoparticle delivery system in cannabis. For more information on
Evolve Formulas, visit
https://www.evolveformulas.com/. Follow us on
Facebook,
Instagram and
Twitter.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in
this news release which are not purely historical are forward looking statements, including without limitation any statements
concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes
that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking
statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without
limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be
assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from
those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and
uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the
date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons
why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new
information, future events or otherwise.
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES
Gary Symons
Mobile: 250-300-9352
E-mail: gsymons@nanospherehealth.com
On behalf of the Board
Robert Sutton, Chairman and CEO
Office: 720-845-1466
Email: rsutton@nanospherehealth.com
Investor contact:
Victor Goncalves, Executive Vice President
Mobile: 204-997-5517
E-mail: vgoncalves@nanospherehealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190117005329/en/